首页> 外国专利> VACCINE FOR PROPHYLAXIS AND TREATMENT OF T-CELLS MEDIATED PATHOLOGY OR NONREGULATED REPLICATION BY T-CELL CLONES, METHOD OF ISOLATION OF VACCINE, METHOD OF DIAGNOSIS OR PROGNOSIS OF SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS OF CEREBROSPINAL SCLEROSIS, METHOD OF PROPHYLAXIS OR TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS OR CEREBROSPINAL SCLEROSIS AND PEPTIDE CONTAINING SEQUENCE SGDQGGNE AS AGENT FOR DETECTION, PROPHYLAXIS AND TREATMENT OF PATIENTS WITH CEREBROSPINAL SCLEROSIS

VACCINE FOR PROPHYLAXIS AND TREATMENT OF T-CELLS MEDIATED PATHOLOGY OR NONREGULATED REPLICATION BY T-CELL CLONES, METHOD OF ISOLATION OF VACCINE, METHOD OF DIAGNOSIS OR PROGNOSIS OF SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS OF CEREBROSPINAL SCLEROSIS, METHOD OF PROPHYLAXIS OR TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS OR CEREBROSPINAL SCLEROSIS AND PEPTIDE CONTAINING SEQUENCE SGDQGGNE AS AGENT FOR DETECTION, PROPHYLAXIS AND TREATMENT OF PATIENTS WITH CEREBROSPINAL SCLEROSIS

机译:用于T细胞克隆的病理学治疗和T细胞介导的病理学或非调节性复制的疫苗,疫苗的分离方法,对鼻窦炎或脊髓炎性关节炎的类风湿性关节炎的类风湿性关节炎的诊断或预后诊断方法,或含有序列SGDQGGNE的脑脊柱硬化和肽序列作为检测,预防和治疗脑脊柱硬化的患者的代理

摘要

FIELD: medicine, immunology. SUBSTANCE: invention proposes a vaccine for prophylaxis and treatment of patients with T-cells mediated pathology or nonregulated replication of mammals T-cells that contains an active substance and pharmaceutically tolerantable medium. It has receptor of T-cells or its fragment corresponding to T-cells receptor as an active substance and located on surface mediating this pathology or anti-idiotypic antibodies that are an internal image of this receptor or its mentioned fragment. An active substance is taken at immunogenic effective amount. Vaccine is prepared by preparing T-cell clones causing T-cells mediated pathology and involves the determination of amino acid sequence of receptors of T-cells of clones of T-cells associated with this pathology, selection of fragments of these T-cell receptors which are typical for mentioned receptors of T-cells rather then for receptors of T-cells not associated with this pathology. Then method involves the selection of nonmentioned sequences that are able to induction of immunogenic response with respect to mentioned T-cells receptors that results to the vaccine selection. Also, invention proposes a method of diagnosis or prognosis of the person susceptibility to rheumatoid arthritis that involves the detection of T-cells containing variable site of -strand: MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKQNVTLSCEQNLNDAMYWYRQDPGQGLRL- -IYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASS or its fragment in the person sample. Anomalous expression of T-cells containing this site indicates the presence of rheumatoid arthritis or susceptibility to rheumatoid arthritis and a method of prophylaxis and treatment of patients with rheumatoid arthritis. Method involves the prevention of binding T-cells receptor containing the sequence: MSNQVLCCVVLCFLGANTVDGGITQSP- -KYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLLIYYSQIVNDFQKGDIAEGYSVS- -REKKESFPLTVTSAQKNPTAFYLCASS or T-cells receptor containing mainly the sequence SGDQGGNE with its partner and a method of prophylaxis and treatment of patients with rheumatoid arthritis. Method involves cytotoxic or cytostatic treatment of T-cells, the sequence MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNH- -DAMYWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSPEKKESFPLTVTSAQKNPTAFY- -CASS or T-cells containing mainly the sequence SGDGGNE in the person. EFFECT: vaccine indicated above, improved method of prophylaxis and treatment, active peptide. 21 cl, 10 tbl, 9 ex
机译:领域:医学,免疫学。发明内容本发明提出了一种用于预防和治疗具有T细胞介导的病理学或哺乳动物T细胞的非受控复制的患者的疫苗,该疫苗包含活性物质和可药用的介质。它具有T细胞受体或其对应于T细胞受体的片段作为活性物质,并位于介导该病理或抗独特型抗体的表面上,该抗体是该受体或其片段的内部图像。以免疫原有效量服用活性物质。疫苗是通过制备引起T细胞介导的病理的T细胞克隆制备的,涉及确定与该病理相关的T细胞克隆的T细胞受体的氨基酸序列,选择这些T细胞受体的片段,对于所提到的T细胞受体而言是典型的,而不是与这种病理学无关的T细胞受体是典型的。然后该方法涉及选择未提及的序列,该序列能够针对导致疫苗选择的提及的T细胞受体诱导免疫原性应答。另外,本发明提出了一种诊断或预后人类风湿性关节炎的方法,该方法包括检测含有-链可变位点的T细胞:含有该位点的T细胞的异常表达表明类风湿关节炎的存在或对类风湿关节炎的敏感性以及预防和治疗类风湿关节炎患者的方法。方法包括预防含有以下序列的T细胞受体的结合:MSNQVLCCVVLCFLGANTVDGGITQSP- -KYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLLILIYYSQIVNDFQKGDIAEGYSVS- -REKKESFPLTVTSAQKNPTAFYLCASS或与T细胞受体结合的方法与原发性SGD受体治疗或与T细胞受体结合的方法与原发性SGD受体治疗方法结合。方法涉及对T细胞的细胞毒性或细胞抑制性治疗,序列MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNH- -DAMYWYRQDPGQGLRLIYYYSQIVNDFQKGDIAEGYSVSPEKKESFPLTVTSAQKNPTAFY- -CASS或T细胞包含在S细胞或T细胞中。效果:上述疫苗,预防和治疗方法的改进,活性肽。 21厘升,10汤匙,9厘

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号